1-3 of 3
Ida Blok Sillesen
Close
Sort by
Journal Articles

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Michael Roost Clausen, MD, Sirpa Leppa, MD, Peter de Nully Brown, MD, Jette Soenderskov Goerloev, MD, Michael Panny, MD, Wolfgang Willenbacher, MD, Ida Blok Sillesen, MD, Erik Segel, MD, Hans Bentzen, MD, Michael Thorsgaard, MD, Elisa Jacobsen Pulczynski, MD, Peter Kamper, MD, Lars C. Gormsen, MD, Julie Mortensen, MDcal Student, Grethe Lauritzsen, MD, Thomas Relander, MD PhD, Francesco d'Amore, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1782.
https://doi.org/10.1182/blood.V128.22.1782.1782
Published: 2016
Journal Articles

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Francesco d'Amore, Judit Joergensen, Ida Blok Sillesen, Erik Segel, Hans Bentzen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Bjarne Bach Pedersen, Dorte Gillström, Michael Clausen, Peter Kamper, Trine Silkjaer, Lars C. Gormsen, Sirpa Leppä, Helle Toldbod
Journal: Blood
Blood (2014) 124 (21): 5435.
https://doi.org/10.1182/blood.V124.21.5435.5435
Published: 2014
Journal Articles

Prognostic Impact of Clinician-Based Interpretation of FDG-PET/CT Reports Obtained in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma.

Karen Juul Mylam, Tarec Christoffer El-Galaly, Peter de Nully Brown, Bodil Himmelstrup, Dorte Gillstrøm, Ida Blok Sillesen, Lars Munksgaard, Bjarne Bach Pedersen, Ilse Christiansen, Paw Jensen, Anne Lerberg Nielsen, Lars Møller Pedersen
Journal: Blood
Blood (2012) 120 (21): 2646.
https://doi.org/10.1182/blood.V120.21.2646.2646
Published: 2012